(2,5-dioxo-4-phenyl-imidazolidin-4-yl)-acetic acid | 62985-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (2,5-dioxo-4-phenyl-imidazolidin-4-yl)-acetic acid
• 英文别名: (2,5-Dioxo-4-phenyl-imidazolidin-4-yl)-essigsaeure；2-(2,5-Dioxo-4-phenylimidazolidin-4-yl)acetic acid
• CAS: 62985-01-7
• 化学式: C₁₁H₁₀N₂O₄
• 分子量: 234.211
• InChiKey: NZNUMNLHZBSSJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (2,5-dioxo-4-phenyl-imidazolidin-4-yl)-acetic acid ethyl ester 在 盐酸 作用下， 生成 (2,5-dioxo-4-phenyl-imidazolidin-4-yl)-acetic acid
  参考文献：
  名称：

  The Preparation of Certain 5-Acetates and 5-Acetamides of 5-Phenylhydantoin¹

  摘要：

  DOI：

  10.1021/ja01853a046

文献信息

• [EN] 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12.<br/>[FR] 2,5-DIOXOIMIDAZOLIDINE-4-YL ACETAMIDES ET ANALOGUES SERVANT D'INHIBITEURS DE LA METALLOPROTEINASE MMP12.
  申请人：ASTRAZENECA AB

  公开号：WO2004020415A1

  公开（公告）日：2004-03-11

  The invention provides compounds of formula (I) in which L, X, Y, Z1, Z2, R1, R2, R3 and G2 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds of the invention are inhibitors of metalloproteinase MMP12 and are among other things useful for the treatment of obstructive airways diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

  该发明提供了式（I）中的化合物，其中L、X、Y、Z1、Z2、R1、R2、R3和G2的含义如规范中所定义；它们的制备方法；含有它们的药物组合物；制备药物组合物的方法；以及它们在治疗中的用途。该发明的化合物是金属蛋白酶MMP12的抑制剂，除其他用途外，还可用于治疗阻塞性气道疾病，如哮喘和慢性阻塞性肺病（COPD）。
• 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
  申请人：Henriksson Krister

  公开号：US20050245586A1

  公开（公告）日：2005-11-03

  The invention provides compounds of formula (I) in which L, X, Y, Z 1 , Z 2 , R 1 , R 2 , R 3 and G 2 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds of the invention are inhibitors of metalloproteinase MMP12 and are among other things useful for the treatment of obstructive airways diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

  本发明提供了公式（I）的化合物，其中L、X、Y、Z1、Z2、R1、R2、R3和G2的含义在说明书中定义；它们的制备过程；包含它们的制药组合物；制备制药组合物的过程；以及它们在治疗中的应用。本发明的化合物是金属蛋白酶MMP12的抑制剂，可用于治疗阻塞性呼吸道疾病，如哮喘和慢性阻塞性肺疾病（COPD）等疾病。
• 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
  申请人：Henriksson Krister

  公开号：US20060276524A1

  公开（公告）日：2006-12-07

  The invention provides compounds of formula in which L, X, Y, Z 1 , Z 2 , R 1 , R 2 , R 3 and G 2 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.

  该发明提供了公式化合物，其中L、X、Y、Z1、Z2、R1、R2、R3和G2的含义在规范中定义；制备它们的过程；包含它们的制药组合物；制备制药组合物的过程；以及它们在治疗中的应用。
• Spiro-3-hetero-azolones for treatment of diabetic complications
  申请人：PFIZER INC.

  公开号：EP0115133A1

  公开（公告）日：1984-08-08

  Compounds of the formula and their pharmaceutically acceptable salts, wherein: U is oxygen, sulfur or nitrogen substituted with hydrogen or alkyl having 1-4 carbon atoms; n is zero or one; W is carbonyl or hydroxymethylene; R is hydrogen or alkyl having 1-4 carbon atoms; X is hydrogen, chloro, bromo, iodo, alkyl having 1-4 carbon atoms, dimethyl or (CH2)mQ wherein m is 1 or 2 and Q is phenyl or halophenyl, with the proviso that when X is dimethyl, n is one; Y is hydrogen, halo, nitro, trifluoromethyl, alkoxy having 1-4 carbon atoms or alkyl having 1-4 carbon atoms; and Z is hydrogen, halo, nitro, trifluoromethyl, alkoxy having 1-4 carbon atoms or alkyl having 1-4 carbon atoms, with the proviso that if either Y or Z is nitro the other is hydrogen. The compounds are useful in the treatment of certain chronic complications arising from diabetes mellitus, such as diabetic cataracts, retinopathy and neuropathy.

  式中的化合物 及其药学上可接受的盐类，其中 U 是被氢或具有 1-4 个碳原子的烷基取代的氧、硫或氮； n 为 0 或 1 W 是羰基或羟基亚甲基； R 是氢或具有 1-4 个碳原子的烷基； X 是氢、氯、溴、碘、具有 1-4 个碳原子的烷基、二甲基或 (CH2)mQ，其中 m 是 1 或 2，Q 是苯基或卤代苯基，但当 X 是二甲基时，n 是 1； Y 是氢、卤素、硝基、三氟甲基、具有 1-4 个碳原子的烷氧基或具有 1-4 个碳原子的烷基；及 Z 是氢、卤素、硝基、三氟甲基、具有 1-4 个碳原子的烷氧基或具有 1-4 个碳原子的烷基，但如果 Y 或 Z 是硝基，则另一个是氢。 这些化合物可用于治疗糖尿病引起的某些慢性并发症，如糖尿病性白内障、视网膜病变和神经病变。
• Spiro-imidazolidines as aldose reductase inhibitors
  申请人：PFIZER INC.

  公开号：EP0203791A1

  公开（公告）日：1986-12-03

  Spiro-imidazolidines of the formula: and the pharmaceutically acceptable salts thereof, wherein X is 0, CH2 or NH; R is hydrogen, fluoro, chloro, methyl or methoxy; and Y is O or CH2. These compounds are useful in treatment to prevent or alleviate ocular or neuritic diabetes-associated chronic complications.

  式中的螺咪唑烷类及其药学上可接受的盐类 及其药学上可接受的盐类，其中 X 是 0、CH2 或 NH；R 是氢、氟、氯、甲基或甲氧基；Y 是 O 或 。 这些化合物可用于预防或缓解眼部或神经性糖尿病相关慢性并发症的治疗。